8-K: Oncology Institute Rebrands as Starling Oncology

The Oncology Institute, Inc. has officially rebranded to Starling Oncology, Inc., with its stock set to trade under the new ticker symbol STLN on Nasdaq.

Summary

• The Oncology Institute, Inc. has officially changed its name to Starling Oncology, Inc., effective immediately on July 28, 2026.
• The company's common stock will begin trading on the Nasdaq Stock Market LLC under the new ticker symbol 'STLN' on August 3, 2026, replacing the previous symbol 'TOI'.
• This name change was accomplished through a Certificate of Amendment to the company's Certificate of Incorporation and did not require stockholder approval.
• The rebranding reflects the company's growth, its evolution into an integrated oncology platform, and its commitment to value-based, community-based cancer care.
• Patients, providers, and payers will experience no disruption in services, with existing contact points and portal access remaining the same.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, reflecting the company's growth and strategic evolution. The rebranding signifies a maturing business aiming for broader recognition and market positioning.

Positives

• The rebranding to Starling Oncology, Inc. signifies a strategic evolution and growth for the company.
• The new ticker symbol 'STLN' on Nasdaq is intended to reflect the company's scale and upward trajectory.
• The company emphasizes its commitment to value-based, patient-centered cancer care and solving the cost crisis in oncology.
• The transition is designed to be seamless for patients, providers, and payers, with no disruption to care.
• Starling Oncology serves approximately 2.1 million patients with over 400 clinicians and more than 100 clinics across five states.

Negatives

• No specific negative financial or operational information was disclosed in this filing.

Risks

• The company operates in a highly regulated industry, and changes in healthcare policy or reimbursement could impact its business model.
• Competition within the oncology sector is intense, and maintaining market share and attracting new patients will be crucial.
• The success of the value-based care model depends on effective risk management and achieving positive patient outcomes.
• Integration of new technologies and expansion into new markets carry inherent operational and financial risks.

Future Outlook

The rebranding to Starling Oncology, Inc. and the new ticker symbol STLN are presented as part of the company's continued growth and evolution into an integrated oncology platform, with a mission to solve the cost crisis in oncology and deliver high-quality, patient-centered care.

Management Comments

• "Starling Oncology is a name that reflects our scale and our continued upward trajectory as an organization. Like starlings in flight, our coordinated delivery model emphasizes accessibility and teamwork that defines our commitment to community-based cancer care."
• "Our name is changing, but our mission remains steadfast: delivering high-quality, patient-centered cancer care to the communities we serve, with a focused ambition to help solve the cost crisis in oncology."
• "We have proven that we have a better solution for both payers and the patients who trust us with accessible, outcomes-focused, high-quality medical care."

Industry Context

StockSavvy.ai notes that the rebranding aligns with a broader trend in healthcare, particularly in specialized fields like oncology, to consolidate and present a more integrated, value-driven service offering. The shift to a new ticker symbol on Nasdaq also suggests a move towards greater market visibility and potentially attracting a wider investor base.

Corporate Governance

Stakeholder Impact

• Shareholders: No change in rights; potential for increased visibility and investor interest due to rebranding and new ticker symbol.
• Patients: No disruption to care; continued access to services and points of contact.
• Providers: No disruption to services or points of contact.
• Payers: No disruption to services or points of contact; continued focus on value-based care model.

Next Steps

• Common stock to begin trading under the new ticker symbol STLN on Nasdaq effective August 4, 2026.
• Continued focus on delivering high-quality, patient-centered cancer care.
• Continued efforts to solve the cost crisis in oncology.

Key Dates

Keywords

Starling Oncology, The Oncology Institute, name change, rebranding, ticker symbol, Nasdaq, value-based care, oncology